Document is current
Any future updates will be listed below
-
Authors
Liao, Chen https://orcid.org/0000-0001-8474-1196
Rolling, Thierry
Djukovic, Ana https://orcid.org/0000-0001-8068-7188
Fei, Teng https://orcid.org/0000-0001-7888-1715
Mishra, Vishwas
Liu, Hongbin
Lindberg, Chloe
Dai, Lei https://orcid.org/0000-0002-5598-5308
Zhai, Bing https://orcid.org/0000-0001-6571-7465
Peled, Jonathan U. https://orcid.org/0000-0002-4029-7625
van den Brink, Marcel R. M. https://orcid.org/0000-0003-0696-4401
Hohl, Tobias M. https://orcid.org/0000-0002-9097-5412
Xavier, Joao B. https://orcid.org/0000-0003-3592-1689
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R01 AI137269, R01 AI093808, R21 AI156157)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U54 CA209975)
Deutsche Forschungsgemeinschaft (RO-5328/1-2 (T.R.))
- License Information
-
More Information
Article History
Received: 24 October 2022
Accepted: 20 March 2024
First Online: 2 May 2024
Competing interests
: J.U.P. reports research funding, intellectual property fees and travel reimbursement from Seres Therapeutics, and consulting fees from DaVolterra, CSL Behring, Crestone, Inc. and Maat Pharma. He serves on an Advisory board of and holds equity in Postbiotics Plus Research. He has filed intellectual property applications related to the microbiome (reference numbers 62/843,849, 62/977,908 and 15/756,845). M.R.M.v.d.B. has received research support from Seres Therapeutics; he has consulted, received honorarium from or participated in advisory boards for Seres Therapeutics, WindMIL Therapeutics, Rheos, Frazier Healthcare Partners, Nektar Therapeutics, Notch Therapeutics, Forty Seven Inc., Priothera, Ceramedix, Lygenesis, Pluto Immunotherapeutics, Magenta Therapeutics, Merck & Co., Inc. and DKMS Medical Council (Board); and he has IP Licensing with Seres Therapeutics and Juno Therapeutics and stock options from Seres and Notch Therapeutics. T.M.H. has participated in a scientific advisory board for Boehringer-Ingelheim Inc. T.R. is currently an employee of BioNTech SE. The Memorial Sloan Kettering Cancer Center (MSKCC) has financial interests relative to Seres Therapeutics. The other authors declare no competing interests.
